弥漫性大B细胞淋巴瘤免疫治疗进展

弥漫性大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）是最常见的非霍奇金淋巴瘤（NHL）亚型，其具有高度异质性和侵袭性。尽管许多患者应用R-CHOP(利妥昔单抗+环磷酰胺+阿霉素+长春新碱+泼尼松)方案一线治疗后达到完全缓解（CR），但仍有部分患者之后发展为复发和难治性的DLBCL，而一旦发展为复发难治性的DLBCL，常规的放疗和化疗则收效甚微。近年来，免疫治疗逐渐成为研究热点，如单克隆抗体治疗、双特异性抗体治疗、抗体-药物偶连物（ADC）治疗和嵌合体抗原受体修饰T细胞（CAR-T）治疗等。本文现就弥漫性大B细胞淋巴瘤免疫治疗进展进行综述。

Progress in immunotherapy for diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma(DLBCL) is the most common subtype of non-Hodgkin's lymphoma(NHL),which is highly heterogeneous and invasive.Although many patients achieved complete remission(CR) after first-line treatment with the R-CHOP(rituximab+cyclophosphamide+doxorubicin+vincristine+prednisone) regimen,some patients developed relapse afterwards and refractory DLBCL,and once developed into relapsed refractory DLBCL,conventional radiotherapy and chemotherapy have little effect.In recent years,immunotherapy has gradually become a research hotspot,such as monoclonal antibody therapy,bispecific antibody therapy,antibody-drug conjugate(ADC) therapy and chimeric antigen receptor modified T cell(CAR-T) therapy.This article now reviews the progress of immunotherapy for diffuse large B-cell lymphoma.